Form 4: Castle Biosciences COO Sells Shares in Pre-Planned Trade

Castle Biosciences' Chief Operating Officer, Kristen M Oelschlager, sold 14,888 shares of common stock for a weighted-average price of $39.313 per share.

Summary

• Kristen M Oelschlager, Chief Operating Officer of Castle Biosciences Inc. (CSTL), executed a sale of common stock.
• The transaction involved the disposition of 14,888 shares of common stock on December 17, 2025.
• The shares were sold at a weighted-average price of $39.313 per share, with individual trades ranging from $39.055 to $39.830.
• This transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following the reported transaction, Kristen M Oelschlager directly beneficially owns 12,323 shares of common stock.
• Additionally, 97,251 shares are indirectly beneficially owned through The Fritz Shorter Trust, where the Reporting Person and her spouse serve as trustees and beneficiaries.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned sale under a Rule 10b5-1 plan, which typically indicates a routine personal financial management event rather than a signal of management's view on the company's immediate prospects. Therefore, the sentiment is neutral.

Industry Context

This is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. Insider sales, especially those executed under a 10b5-1 plan, are common for executive compensation and personal financial planning.

Related Party Transactions

• 97,251 shares are indirectly beneficially owned through The Fritz Shorter Trust, of which the Reporting Person and her spouse are the trustees and beneficiaries.

Stakeholder Impact

• Shareholders may note the sale by a key executive, though its execution under a 10b5-1 plan mitigates concerns about its signaling effect on company performance.

Key Dates

Keywords

Castle Biosciences, CSTL, Insider Sale, Officer Transaction, Stock Sale, Kristen M Oelschlager, Form 4, 10b5-1 Plan